Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Xeris Biopharma Holdings, Inc.
Xeris Biopharma Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
July 25, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Announces CEO Succession Plan
July 08, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 03, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
June 03, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
May 30, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
May 09, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
May 06, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
May 02, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 03, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
March 06, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
March 06, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
February 28, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
February 05, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
January 10, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 05, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Updates Its Outlook for 2023
January 04, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023
October 16, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Announces Private Convertible Note Exchange Transactions
September 27, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris to Participate in the 2023 Cantor Global Healthcare Conference
September 14, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023
August 01, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Ships One Millionth Gvoke® Unit
July 31, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism
June 21, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Xeris Biopharma to Participate at the Jefferies Healthcare Conference
June 01, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Tickers
XERS
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.